title: Episomal viral cDNAs identify a reservoir that fuels viral rebound after treatment interruption and that contributes to treatment failure.
abstract: Viral reservoirs that persist in HIV-1 infected individuals on antiretroviral therapy (ART) are the major obstacle to viral eradication. The identification and definition of viral reservoirs in patients on ART is needed in order to understand viral persistence and achieve the goal of viral eradication. We examined whether analysis of episomal HIV-1 genomes provided the means to characterize virus that persists during ART and whether it could reveal the virus that contributes to treatment failure in patients on ART. For six individuals in which virus replication was highly suppressed for at least 20 months, proviral and episomal genomes present just prior to rebound were phylogenetically compared to RNA genomes of rebounding virus after therapy interruption. Episomal envelope sequences, but not proviral envelope sequences, were highly similar to sequences in rebounding virus. Since episomes are products of recent infections, the phylogenetic relationships support the conclusion that viral rebound originated from a cryptic viral reservoir. To evaluate whether the reservoir revealed by episomal sequence analysis was of clinical relevance, we examined whether episomal sequences define a viral population that contributes to virologic failure in individuals receiving the CCR5 antagonist, Vicriviroc. Episomal envelope sequences at or near baseline predicted treatment failure due to the presence of X4 or D/M (dual/mixed) viral variants. In patients that did not harbor X4 or D/M viruses, the basis for Vicriviroc treatment failure was indeterminate. Although these samples were obtained from viremic patients, the assay would be applicable to a large percentage of aviremic patients, based on previous studies. Summarily, the results support the use of episomal HIV-1 as an additional or alternative approach to traditional assays to characterize virus that is maintained during long-term, suppressive ART.
authors.affiliation: Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America.
authors.forename: Mark
authors.initials: M
authors.lastname: Sharkey
authors.forename: Dunja Z
authors.initials: DZ
authors.lastname: Babic
authors.forename: Thomas
authors.initials: T
authors.lastname: Greenough
authors.forename: Roy
authors.initials: R
authors.lastname: Gulick
authors.forename: Daniel R
authors.initials: DR
authors.lastname: Kuritzkes
authors.forename: Mario
authors.initials: M
authors.lastname: Stevenson
mesh_terms: D000293:Adolescent; D023241:Antiretroviral Therapy, Highly Active; D065100:CCR5 Receptor Antagonists; D018076:DNA, Complementary / Q000235:genetics*; D024882:Drug Resistance, Viral / Q000235:genetics; D016679:Genome, Viral; D015658:HIV Infections / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology; D015497:HIV-1 / Q000235:genetics*; D006801:Humans; D010802:Phylogeny; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D012367:RNA, Viral; D017211:Treatment Failure; D019562:Viral Load; D014766:Viremia / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology; D014779:Virus Replication
chemical_list: D065100:CCR5 Receptor Antagonists; D018076:DNA, Complementary; D010879:Piperazines; D011743:Pyrimidines; D012367:RNA, Viral; C486781:vicriviroc